Comparative Overview of Ipamorelin and CJC-1295

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview

Both ipamorelin and CJC-1295 are categorized as growth hormone secretagogues, though they act through distinct biological pathways. While each agent enhances endogenous growth hormone secretion, their differences in receptor activity, pharmacokinetics, and systemic effects are clinically relevant. Understanding these variations is critical for experimental application and may highlight potential synergistic roles in combined use.

Mechanistic Pathways

Ipamorelin functions as an agonist at the growth hormone secretagogue receptor (GHS-R), mimicking the action of ghrelin. By stimulating GHS-R within the anterior pituitary, it promotes growth hormone release. Additionally, GHS-R subtypes are distributed across the central nervous system, where they influence processes such as cognition, sleep regulation, appetite, glucose homeostasis, and pain modulation.

CJC-1295, in contrast, is an analogue of growth hormone–releasing hormone (GHRH) and selectively binds to GHRH receptors in the anterior pituitary. Unlike ipamorelin, GHRH receptors are not widely expressed beyond the pituitary, confining the direct actions of CJC-1295 primarily to growth hormone stimulation. Its downstream effects are mediated largely through increases in circulating growth hormone and insulin-like growth factor 1 (IGF-1).

Structural Characteristics

Ipamorelin

• Sequence: Aib-His-D-2Nal-D-Phe-Lys
• Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: ~711.9 g/mol
• CAS: 170851-70-4

CJC-1295

• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
• Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: ~3368 g/mol

CJC-1295 with DAC (Drug Affinity Complex)

• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• Formula: C₁₆₅H₂₆₉N₄₇O₄₆
• Molecular Weight: ~3648 g/mol

Both require parenteral delivery due to extensive degradation in the gastrointestinal tract.

Routes of Administration

CJC-1295 is administered subcutaneously. Ipamorelin offers greater flexibility, with both intravenous and subcutaneous routes available. Intravenous use produces more rapid onset and clearance, allowing precise control in experimental infusion protocols.

Patterns of Growth Hormone Secretion

The pharmacokinetics differ substantially. Ipamorelin exhibits a short half-life of approximately two hours, resulting in transient but pronounced growth hormone peaks. In contrast, CJC-1295—particularly when conjugated with DAC—displays a half-life measured in days, with studies reporting sustained effects up to eight days and extended IGF-1 elevation for several weeks following repeated dosing.

CJC-1295 augments growth hormone in a manner consistent with physiological pulsatility, essentially shifting baseline levels upward without disrupting circadian secretion. Ipamorelin, however, induces a sharp but short-lived deviation from normal secretory patterns, creating opportunities for targeted applications around exercise, sleep, or nutritional timing.

Effects on Adiposity

CJC-1295 was initially studied in the context of abnormal fat distribution syndromes. Renewed interest has emerged in its potential influence on adipose reduction. Ipamorelin has demonstrated up to 14% reduction in fat mass in long-term animal studies, while CJC-1295 is hypothesized to exert greater effects due to its prolonged activity and parallels with tesamorelin, another GHRH analogue that has achieved notable fat mass reductions in clinical trials.

Influence on Lean Mass and Skeletal Tissue

Both agents enhance lean body composition, including skeletal muscle and bone tissue. CJC-1295, by virtue of sustained IGF-1 stimulation, exerts robust effects on muscle accretion. Ipamorelin demonstrates unique skeletal benefits, directly stimulating bone mineralization and deposition through GHS-R activity outside the pituitary. Preclinical research indicates that ipamorelin can counteract glucocorticoid-induced bone loss, restoring normal bone turnover and significantly enhancing bone formation rates.

Reproductive Physiology

Preliminary studies indicate CJC-1295 may support ovulatory function, particularly by increasing follicular IGF-1 concentrations. This mechanism could benefit conditions characterized by disrupted IGF-1 signaling, such as polycystic ovary syndrome. Comparable research with ipamorelin has not yet been conducted, though indirect effects via growth hormone and IGF-1 stimulation are plausible.

Neurological and Gastrointestinal Modulation of Pain

Ipamorelin demonstrates activity in pain perception pathways, likely mediated by its effects on neuropeptide Y signaling. Animal models suggest significant reductions in nociceptive sensitivity, particularly for neuropathic and gastrointestinal pain. This effect is not observed with CJC-1295, as its action is confined to GHRH receptor sites.

Clinical Implications

Both ipamorelin and CJC-1295 effectively elevate endogenous growth hormone, though with distinct temporal and systemic patterns.

• Ipamorelin: Best suited for short-term, high-amplitude stimulation with ancillary effects on bone health, cognition, metabolism, and pain regulation.
• CJC-1295: Provides prolonged, physiologically patterned elevation of growth hormone and IGF-1, favoring sustained changes in body composition and potential reproductive benefits.

These characteristics suggest complementary potential in combined protocols, depending on research objectives and desired outcomes.

REFERENCES

1. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
2. Aagaard, N. K., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P. B., Grønbaek, H., Ørskov, H., Tygstrup, N., & Vilstrup, H. (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(5), 426–431. https://doi.org/10.1016/j.ghir.2009.01.001
3. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
4. Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., & Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569

Product available for research use only: